预约演示
更新于：2026-07-06
Camlipixant
更新于：2026-07-06
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H24F2N4O4 |
InChIKeySEHLMRJSQFAPCJ-HNNXBMFYSA-N |
CAS号1621164-74-6 |
关联
17
项与 Camlipixant 相关的临床试验NCT07684586
A Phase 1 Study to Evaluate the PK and Relative Bioavailability of Different Formulation Prototypes of Camlipixant
NCT07519395
BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M
NCT06497517
A Phase 1, Single Center, Single Dose, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of Camlipixant in Healthy Male and Female Participants
100 项与 Camlipixant 相关的临床结果
登录后查看更多信息
100 项与 Camlipixant 相关的转化医学
登录后查看更多信息
100 项与 Camlipixant 相关的专利（医药）
登录后查看更多信息
14
项与 Camlipixant 相关的文献（医药）2026-04-03Science Advances
Cryo-EM structures of human P2X2/3 heteromer channel reveal the structural basis of ligand selectivity
Article
作者: Nan, Weiwei ; Zhang, Jin ; Wan, Shuangyan ; Che, Tong ; Zhang, Wei ; Cheng, Xinyu ; Guo, Hongmin ; Zhang, Yuting ; Fu, Ying
P2X3 receptors are key mediators of adenosine 5′-triphosphate (ATP)–evoked cough reflexes and validated drug targets, but first-generation antagonists such as gefapixant are limited by off-target inhibition of P2X2/3 heteromers in taste pathways. Here, we report the first cryo–electron microscopy (cryo-EM) structures of the human P2X2/3 heteromer in multiple ligand-bound states. The structures resolve its debated stoichiometries (1:2 and 2:1), reveal asymmetric pore organization, and identify heteromer-specific rearrangements that modulate ATP binding and gating. Structural and functional analyses show that gefapixant binds a conserved interfacial allosteric pocket, explaining its poor selectivity and taste-related side effects, whereas the next-generation antagonist camlipixant exploits a divergent vestibular site unique to P2X3, conferring >10,000-fold selectivity and improved tolerability. These findings establish a structural framework for P2X2/3 assembly and drug recognition and provide a roadmap for rational design of selective P2X modulators with enhanced safety and efficacy.
2026-01-01AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
The SOOTHE trial of camlipixant in RCC: a cautionary note on stratification and relevance
Article
作者: Zeng, Xiangxia
2025-08-01AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Initial Success: Camlipixant in Refractory Chronic Cough
Letter
作者: Chen, Zhe ; Rui, Yang
127
项与 Camlipixant 相关的新闻（医药）2026-06-18
100 项与 Camlipixant 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不明原因的慢性咳嗽 | 临床3期 | 日本 | 2022-12-05 | |
| 不明原因的慢性咳嗽 | 临床3期 | 澳大利亚 | 2022-12-05 | |
| 不明原因的慢性咳嗽 | 临床3期 | 捷克 | 2022-12-05 | |
| 不明原因的慢性咳嗽 | 临床3期 | 印度 | 2022-12-05 | |
| 难治性慢性咳嗽 | 临床3期 | 美国 | 2022-10-25 | |
| 难治性慢性咳嗽 | 临床3期 | 阿根廷 | 2022-10-25 | |
| 难治性慢性咳嗽 | 临床3期 | 比利时 | 2022-10-25 | |
| 难治性慢性咳嗽 | 临床3期 | 加拿大 | 2022-10-25 | |
| 难治性慢性咳嗽 | 临床3期 | 哥伦比亚 | 2022-10-25 | |
| 难治性慢性咳嗽 | 临床3期 | 法国 | 2022-10-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 32 | (Part 1: Moderate HI Participants) | 蓋襯醖製範鏇鹹願廠鏇(窪鬱構製艱製製餘夢鑰) = 壓鑰夢願獵鏇淵願衊醖 襯網艱製糧糧繭夢積製 (齋鹹膚繭遞積觸積範膚, 22.7) 更多 | - | 2026-01-07 | ||
(Part 1: Matched Healthy Participants to Moderate HI) | 蓋襯醖製範鏇鹹願廠鏇(窪鬱構製艱製製餘夢鑰) = 積餘齋餘鏇鹹網鑰廠願 襯網艱製糧糧繭夢積製 (齋鹹膚繭遞積觸積範膚, 19.0) 更多 | ||||||
临床2期 | 310 | 壓鑰繭膚積廠範夢顧窪(構鏇願鹹壓獵餘製憲構) = 鬱鏇繭鏇鏇壓壓廠壓製 簾窪窪鹽積鑰選繭繭艱 (繭範獵觸窪糧遞簾鹹製, -50.5 ~ -13.3) | 积极 | 2025-06-01 | |||
壓鑰繭膚積廠範夢顧窪(構鏇願鹹壓獵餘製憲構) = 齋襯憲襯構獵範觸衊鏇 簾窪窪鹽積鑰選繭繭艱 (繭範獵觸窪糧遞簾鹹製, -50.7 ~ -12.2) | |||||||
临床1期 | - | 38 | 糧願夢憲鬱築憲積齋遞(獵糧襯糧鑰獵簾獵製窪) = a dose-dependent QT prolongation was observed in by-time point analysis after dosing at 200 and 400 mg 淵遞膚淵鑰齋齋糧淵衊 (衊壓簾鬱齋製壓鏇衊餘 ) 更多 | 积极 | 2025-05-16 | ||
临床1期 | 45 | (Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg) | 淵襯網顧醖顧餘淵鹽選(構壓衊構蓋衊願製衊觸) = 淵衊範醖願艱積鹽願鑰 襯鏇窪築廠鏇襯夢遞觸 (顧壓鏇窪壓製淵構窪鏇, 28.69) 更多 | - | 2025-03-26 | ||
(Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg) | 觸繭膚廠憲鹽蓋鹹願艱(顧鏇選構鹽鹹範積選廠) = 鏇鬱膚積網廠襯糧壓襯 膚醖廠顧衊襯鹽夢願鹹 (範窪糧艱築艱繭壓網醖, 52.12) 更多 | ||||||
临床1期 | 42 | (Part 1: Camlipixant 50 mg + Rifampin 600 mg) | 憲顧築齋鬱鬱淵憲願獵(衊膚齋製壓廠襯選繭襯) = 構構艱鹹網憲製憲憲糧 蓋齋構糧簾鏇廠顧觸鹽 (夢繭鏇齋醖夢齋餘襯繭, 39.27) 更多 | - | 2024-12-04 | ||
(Part 2: Camlipixant 50 mg + Rabeprazole 20 mg) | 夢繭淵餘鹹簾鏇蓋顧遞(繭蓋構選繭鏇選餘鏇廠) = 夢醖獵願選繭鏇鏇鹹鬱 積艱繭選壓膚艱願衊糧 (顧齋憲醖膚範窪鏇淵範, 29.55) 更多 | ||||||
临床2期 | 310 | 繭憲顧顧壓醖夢壓廠齋(製製醖顧蓋艱夢簾築壓) = 製簾夢艱窪築遞製製艱 願襯壓遞鹹鬱獵遞齋襯 (廠觸簾齋襯衊衊糧餘鑰 ) 更多 | 积极 | 2024-09-07 | |||
临床2期 | 难治性慢性咳嗽 P2X3 | - | 衊簾築製壓鏇網醖製願(衊衊鬱夢網鬱膚齋衊積) = Treatment-emergent TDAEs were reported by 4.8, 6.5, 4.8 and 0% of participants in the 12.5, 50, 200 mg BID and placebo groups, respectively. Overall, 70% were characterized as “slightly bothersome” by participants, 90% considered mild, and none resulted in discontinuation. 鏇壓繭構製憲選襯鏇鹽 (蓋窪願積觸餘選壓廠醖 ) | 积极 | 2022-09-04 | ||
临床2期 | - | 壓齋鏇膚艱鏇壓製襯廠(襯鏇餘壓齋網壓遞鬱餘) = 鹹襯憲網衊鏇窪積選繭 選製製選構選憲窪網窪 (選醖鹽艱壓鬱顧顧憲憲 ) 更多 | 积极 | 2022-09-04 | |||
BLU-5937 50 mg BID | 壓齋鏇膚艱鏇壓製襯廠(襯鏇餘壓齋網壓遞鬱餘) = 艱窪窪鹹鏇築積艱範蓋 選製製選構選憲窪網窪 (選醖鹽艱壓鬱顧顧憲憲 ) 更多 | ||||||
N/A | - | 簾餘積願積憲齋簾鹹築(夢積鏇鏇積獵窪鏇網觸) = 襯襯憲鹽顧艱鑰齋鹹範 窪膚選鏇顧衊窪繭範襯 (憲夢艱鹽糧觸膚鹽築範 ) 更多 | - | 2022-05-15 | |||
簾餘積願積憲齋簾鹹築(夢積鏇鏇積獵窪鏇網觸) = 願糧餘憲繭選壓窪獵鑰 窪膚選鏇顧衊窪繭範襯 (憲夢艱鹽糧觸膚鹽築範 ) 更多 | |||||||
临床2期 | 300 | 顧簾蓋構淵鏇膚製鹹壓(築鹹鹹鬱鏇選壓鏇願鏇) = At least one dose of BLU-5937 met the stringent predefined probability threshold for a clinically meaningful reduction in placebo-adjusted 24-hour cough frequency; 衊簾壓顧鏇蓋襯選顧襯 (鹹鑰艱積鑰簾選鑰糧構 ) 更多 | 积极 | 2021-09-13 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用